FORMULATION AND EVALUATION OF CONTROLLED POROSITY OSMOTIC PUMP TABLETS FOR ZIDOVUDINE AND LAMIVUDINE COMBINATION USING FRUCTOSE AS OSMOGEN
The present study deals with the development and evaluation of controlled porosity osmotic pump (CPOP) tablets of zidovudine-lamivudine. Wet granulation method was used for the development of core tablets. Core tablets were incorporated with HPMCE5 LV polymer, different concentrations of fructose as osmogen and additives. The CPOP tablets were coated with cellulose acetate as a wall forming material, polyethylene glycol as flux regulating agent, and sorbitol acts as pore forming material in SPM. The formulated tablets were evaluated for FTIR, DSC, pre-compression parameters, post compression parameters, in vitro drug release study and scanning electron microscopy study. The optimized formulation had no significant effect on the pH and agitation intensity, but depends on the osmotic pressure of dissolution media indicated that mechanism of drug release. SEM images revealed that no pores were found before dissolution and after dissolution had shown the porous nature of the membrane. Short term stability study at 40Â±2ÂºC /75Â±5% RH for the months on the CF4 formulation indicated that there was no significant change weight variation, % friability, drug content and in vitro drug release.
Keywords: HPMCE5LV, wet granulation, CPOP, in vitro drug release, stability study.
2. Sahoo CK, Rao SRM, Sudhakar M and Sahoo NK. Advances in osmotic drug delivery system. J of Chemical and Pharmaceutical Research. 2015; 7:252-273.
3. Zenter GM, Rork GS, Himmelstein KJ. The controlled porosity osmotic pump. J control release; 1985; 1:269-282.
4. Verma RK, Krishna DM, Garg S. Formulation aspects in the development of osmotically controlled oral drug delivery systems. J control release; 2000; 79:7-27.
5. Sahoo CK, Sahoo NK, Rao SRM, Sudhakar M. A Review on Prevention and Treatment of Aids. Pharm Pharmacol Int J. 2017; 5(1):00108.
6. Michael J. Mugavero, Charles B. Hicks, HIV resistance and the effectiveness of combination antiretroviral treatment. Drug Discovery Today: Therapeutic strategies 2004; 1(4):529-535.
7. Jilakara VS, Chowdary YA. Formulation and evaluation of sustained release matrix tablets of Zidovudine, Int. J. Pharm. Sci. Rev. Res. 2013; 18(1):143-149.
8. Kumaravelrajan R, Narayanan N, Suba V. Development and evaluation of controlled porosity osmotic pump for Nifedipine and Metoprolol combination. Lipids in Health and Disease.2011; 10:51
9. Sahoo CK, Sahoo NK, Rao SRM, Sudhakar M, Satyanarayana K. A review on controlled porosity osmotic pump tablets and its evaluation. Bulletin of Faculty of Pharmacy, Cairo University, 2015; 53(2):195-205.
10. Sahoo CK, Rao SRM, Sudhakar M. Evaluation of controlled porosity osmotic pump tablets a review. Research J. Pharm. And Tech. 2015; 8(12):119-125.
11. Sirisha VNL, Rao YKK, Eswaraiah MC. Formulation and evaluation of Lamivudine and Zidovudine extended release tablets, Int. J. of Research in Pharmaceutical and Biomedical Sciences.2012;3(4):1759-1763.
12. Costa P, Lobo JMS. Modelling and comparison of dissolution profiles, European J of Pharmaceutical Sciences, 2001; 13:123-133.
13. Sahoo CK, Rao SRM, Sudhakar M and Kokkula S. The kinetic modeling of drug dissolution for drug delivery systems: an overview. Der Pharmacia Lettre 2015; 7(9):186-194.
14. Sharma F, Jain H, Kanzariya V, Upadhyay U. Formulation and evaluation of controlled release osmotic tablet of metoprolol succinate. Asian J. Pharm Clin Res 2014; 7(3):38-43.
15. Banerjee A, Verma PRP, Gore S. Controlled porosity solubility modulated osmotic pump tablets of Gliclazide.AAPS Pharm Sci Tech 2015; 16(3):554-568.
16. Kuksal A, Tiwary AK, Jain NK, Jain S. Formulation and in vitro, in vivo evaluation of extended release matrix tablet of Zidovudine: influence combination of hydrophilic and hydrophobic matrix formers. AAPS Pharm Sci Tech 2006; 7(1):E1-E9.
17. Khan ZA, Tripathi R, Misha B. Design and evaluation of enteric coated microporous osmotic pump tablet (ECMOPT) of quetiapine fumarate for the treatment of psychosis. Acta Poloniae â€“Drug Research 2012; 69(6):1125-1136.
18. Kanagale P, Lohay BB, Misra A, Davadra P, Kini R. Formulation and Optimization of Porous Osmotic Pump based Controlled Release System of Oxybutynin.AAPS Pharm SciTech. 2007; 8(3):E1-E7. Pore former
19. Rao BP, Geetha M, Purushothama N, Sanki U. Optimization and development of swellable controlled porosity osmotic pump tablet for theophylline. Trop. J. Pharm Res.2009; 8(3):247-255.
20. Cartensen JT. Drug stability: Principle and practices, Marcel Dakker, New York, 2nd ed. 1995; 538-550.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).